Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Evotec : to Attend Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 06:38pm CET

By a News Reporter-Staff News Editor at Biotech Week -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced that its management will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, USA; 6th German Corporate Conference, Berenberg/Goldman Sachs in Munich, Germany, and Baader Investment Conference, Munich, Germany, and will be attending Goldman Sachs' 7th Annual Biotech Symposium in London, UK, and Bank of America Merrill Lynch Global Healthcare Conference 2017 in London ,UK. Goldman Sachs' 7th Annual Biotech Symposium, London, UK - Date: Friday, 08 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Morgan Stanley 15th Annual Global Healthcare Conference, New York, USA - Date: Monday, 11 September 2017, 04.50 pm EDT (09.50 pm BST, 10.50 pm CEST)

- Venue: New York, NY, USA

- Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK - Date: Thursday, 14 September 2017

- Venue: London, UK

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG 6th German Corporate Conference, Berenberg/Goldman Sachs, Munich, Germany - Date: Monday, 18 September 2017, 11.00 am CEST (10.00 am BST, 05.00 am EDT)

- Venue: Munich, Germany

- Attendee: Enno Spillner, Chief Financial Officer of Evotec AG Baader Investment Conference, Munich, Germany - Date: Wednesday, 20 September 2017, 05.15 pm CEST (04.15 am BST, 11.15 am EDT)

- Venue: Munich, Germany

Keywords for this news article include: Biotechnology, Evotec AG (see also Evotec AG).

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
12/15 EVOTEC : enters into research collaboration with CRTD to discover novel therapie..
12/13 EVOTEC : Academic Bridge LAB282 with Oxford University celebrating one year of i..
12/13 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
12/13 EVOTEC : Enters into Research Collaboration with CRTD to Discover Novel Therapie..
12/13 EVOTEC : enters into research collaboration with CRTD to discover novel therapie..
12/12 CORRECTION OF A RELEASE FROM 11.12.2 : 40 CET/CEST - Evotec AG: Release accordin..
12/11 EVOTEC : Academic Bridge LAB282 with Oxford University Celebrating One Year of I..
12/11 EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
12/11 EVOTEC : S academic bridge lab282 with oxford university celebrating one year of..
12/04 EVOTEC : receives clinical milestone as part of its discovery alliance with Boeh..
More news
News from SeekingAlpha
12/13 Evotec enters into research collaboration with CRTD to discover therapies for..
11/17 Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid..
11/11 Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran..
11/08 MY JOURNEY TO FINANCIAL INDEPENDENCE : 85-Stock October Portfolio Update - Buyin..
11/08 Evotec AG ADR 2017 Q3 - Results - Earnings Call Slides
Financials (€)
Sales 2017 246 M
EBIT 2017 45,7 M
Net income 2017 28,2 M
Debt 2017 103 M
Yield 2017 -
P/E ratio 2017 66,17
P/E ratio 2018 45,42
EV / Sales 2017 8,47x
EV / Sales 2018 6,31x
Capitalization 1 977 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 €
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG89.40%2 323
CELLTRION, INC.--.--%23 643
IQVIA HOLDINGS INC34.41%21 105
INCYTE CORPORATION-2.16%20 253
LONZA GROUP62.09%19 941
ALNYLAM PHARMACEUTICALS, INC.233.49%12 160